Sagimet Biosciences (SGMT) Cash & Equivalents: 2023-2024
Historic Cash & Equivalents for Sagimet Biosciences (SGMT) over the last 2 years, with Sep 2024 value amounting to $77.0 million.
- Sagimet Biosciences' Cash & Equivalents fell 24.38% to $77.0 million in Q3 2024 from the same period last year, while for Sep 2024 it was $77.0 million, marking a year-over-year decrease of 24.38%. This contributed to the annual value of $75.1 million for FY2023, which is N/A change from last year.
- Per Sagimet Biosciences' latest filing, its Cash & Equivalents stood at $77.0 million for Q3 2024, which was down 19.74% from $96.0 million recorded in Q2 2024.
- In the past 5 years, Sagimet Biosciences' Cash & Equivalents registered a high of $176.8 million during Q1 2024, and its lowest value of $18.5 million during Q2 2023.
- Its 2-year average for Cash & Equivalents is $90.9 million, with a median of $86.5 million in 2024.
- Within the past 5 years, the most significant YoY rise in Sagimet Biosciences' Cash & Equivalents was 418.47% (2024), while the steepest drop was 24.38% (2024).
- Sagimet Biosciences' Cash & Equivalents (Quarterly) stood at $75.1 million in 2023, then dropped by 24.38% to $77.0 million in 2024.
- Its Cash & Equivalents was $77.0 million in Q3 2024, compared to $96.0 million in Q2 2024 and $176.8 million in Q1 2024.